Stock Track | Hims & Hers Health Soars 5.72% After 35% Plunge Following Novo Nordisk Partnership Termination

Stock Track

06/24

Hims & Hers Health Inc. (HIMS) experienced a volatile trading session on Tuesday, with its stock soaring 5.72% after a dramatic 35% plunge the previous day. The turbulence comes in the wake of Danish ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1116119736"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116119736\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116119736?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 14:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116119736","market":"sg","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 5.72% After 35% Plunge Following Novo Nordisk Partnership Termination","media":"Stock Track","content":"<div>\n<p>Hims & Hers Health Inc. (HIMS) experienced a volatile trading session on Tuesday, with its stock soaring 5.72% after a dramatic 35% plunge the previous day. The turbulence comes in the wake of Danish ...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 5.72% After 35% Plunge Following Novo Nordisk Partnership Termination</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 5.72% After 35% Plunge Following Novo Nordisk Partnership Termination\n</h2>\n\n<h4 class=\"meta\">\n\n2025-06-24 14:42 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hims & Hers Health Inc. (HIMS) experienced a volatile trading session on Tuesday, with its stock soaring 5.72% after a dramatic 35% plunge the previous day. The turbulence comes in the wake of Danish ...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1116119736","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116119736","pubTimestamp":1750747353,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc.  experienced a volatile trading session on Tuesday, with its stock soaring 5.72% after a dramatic 35% plunge the previous day. The turbulence comes in the wake of Danish pharmaceutical giant Novo Nordisk's decision to terminate its collaboration with Hims & Hers for the sale of weight loss drugs, including the popular Wegovy.The partnership, which began in April, ended abruptly due to what Novo Nordisk described as \"deceptive promotion and selling of illegitimate, knockof","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票轨迹Hims&Hers Health在诺和诺德终止合作关系后暴跌35%后飙升5.72%","themeId":"0e4f87550d613fe05f12a314ce8a1e93","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a volatile trading session on Tuesday, with its stock soaring 5.72% after a dramatic 35% plunge the previous day. The turbulence comes in the wake of Danish pharmaceutical giant Novo Nordisk's decision to terminate its collaboration with Hims & Hers for the sale of weight loss drugs, including the popular Wegovy.\nThe partnership, which began in April, ended abruptly due to what Novo Nordisk described as \"deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.\" In response, Hims & Hers CEO Andrew Dudum countered these claims, stating that Novo Nordisk was \"misleading the public\" and had pressured his company to \"control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients.\"\nThe market's reaction to this news was initially severe, with HIMS stock plummeting 35% during Monday's regular trading session. However, the stock showed signs of recovery in after-hours trading on Monday and continued its rebound on Tuesday. This suggests that investors may be reassessing the impact of the partnership dissolution on Hims & Hers' business model. The company's commitment to maintaining a diverse range of treatment options, including compounded medications, could be viewed positively by some market participants.\nAdding to the stock's volatility, Needham downgraded Hims & Hers from Buy to Hold following the Novo Nordisk fallout. Despite these challenges, the stock's resilience on Tuesday indicates that some investors see potential in the company's ability to navigate this setback and continue serving its customer base with a variety of treatment options.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}